Replies to post #11307 on Intellect Neurosciences Inc. (fka ILNS)

[qotsa55]

If you are talking about solanezumab when you say Soley then you would be wrong about that. Intellect has no involvement with solanezumab. Bapi and Ponzeumab are both being retested in phase 2 on patients in the earliest stages of the disease I believe, so both of those drugs are years and years away from gaining any FDA approval, if they in fact gained approval. OX1 is recruiting for phase 1b and since Shire has bought Viopharma Im not sure what pace they intend to bring OX1 along. So OX1 is still quite a few years away from gaining any FDA approval (If it does gain approval). I think a buyout is more likely soon, I can't see Intellect still being around years from now when and if any of their science gains FDA approval. GLTY